SUMMARY
# Proposed experiment from debate on Synaptic pruning by microglia in early AD
## Background and Rationale
# Expanded Experimental Description: CX3CR1-Targeted Positive Allosteric Modulators in Alzheimer's Disease Neuroinflammation
The proposed investigation addresses a critical gap in understanding the role of microglial CX3CR1 signaling in synaptic preservation during early Alzheimer's disease pathogenesis. The chemokine receptor CX3CR1, which binds the fractalkine ligand (CX3CL1), serves as
METHODOLOGY NOTES
**Phase 1: Experimental Setup and Model Validation (Weeks 1-2)**
• Acquire three AD mouse models: 5xFAD, APP/PS1, and 3xTg-AD mice (n=15 per model per time point)
• Validate baseline CX3CR1 expression via qRT-PCR and immunofluorescence in 2, 4, and 8-month-old mice
• Confirm microglial activation status using Iba1, CD68, and TREM2 markers
• Establish baseline cognitive function using Morris water maze and novel object recognition
**Phase 2: PAM Treatment Design and Administration (Weeks 3-14)**
• Prepare CX3CR1 PAMs: selective compound JMS-17-2 (microglia-specific) and broad-spectrum compound AZD8797
• Administer treatments via osmotic minipumps: vehicle control, low dose (1 mg/kg/day), medium dose (5 mg/kg/day), high dose (15 mg/kg/day)
• Monitor body weight, motor function, and general health weekly
• Collect blood samples at weeks 6, 9, and 12 for peripheral inflammatory markers
**Phase 3: Neuroinflammatory Assessment (Weeks 12-14)**
• Harvest brain tissue from n=8 mice per group